US Cases/Year
~13,800
Approximately 13,800 new cases and 4,360 deaths per year in the United States. Incidence has declined dramatically in screened populations but remains high in underserved communities.[2]
What Is It
Definition, mechanism, and the clinical reality of cervical cancer at end of life. What the hospice team needs to understand on day one.
Global Deaths/Year
~342,000
85% of cervical cancer deaths occur in low- and middle-income countries, making this one of the most inequitably distributed cancer deaths in the world. Nearly all are preventable.[1]
Median Age at Diagnosis
50 years
Peak incidence in the 35–44 age range — younger than any other gynecologic cancer. Many patients have dependent children. This demographic reality shapes every clinical and psychosocial decision.[2]
HPV Attribution
>99%
Virtually all cervical cancers are caused by persistent infection with high-risk human papillomavirus strains. HPV vaccination prevents over 90% of cervical cancers. This is a preventable disease.[3]
Cervical cancer is a malignancy arising from the transformation zone of the uterine cervix, driven almost exclusively by persistent infection with high-risk human papillomavirus (HPV) strains — principally HPV 16 and HPV 18. It is unique among solid tumors in that it is almost entirely preventable through HPV vaccination and early detection via Pap smear screening, yet it remains the fourth most common cancer in women worldwide and a leading cause of cancer death in low- and middle-income countries. In the United States, women who die of cervical cancer are overwhelmingly those who were not reached by screening or vaccination — a reality that carries profound implications for how hospice teams approach this patient population.[3][1]
At end of life, cervical cancer is defined by a convergence of four devastating clinical problems: severe pelvic pain from tumor invasion of the lumbosacral plexus and pelvic sidewall structures; fistula formation between the vagina and bladder (vesicovaginal fistula) or vagina and rectum (rectovaginal fistula); bilateral ureteral obstruction causing hydronephrosis and progressive renal failure; and hemorrhage from tumor erosion into pelvic vasculature. These problems frequently coexist. The patient population is younger than the typical hospice census — women in their 30s, 40s, and 50s — and many have school-age children at home. Every clinical decision in this disease must account for both the medical complexity and the demographic reality.[7]
🧭 Clinical framing
Cervical cancer at end of life is defined by four converging clinical problems — pelvic pain from tumor invasion of nerves and pelvic sidewall, fistula formation between the bladder and vagina or rectum and vagina, ureteral obstruction causing hydronephrosis and renal failure, and hemorrhage from tumor erosion into pelvic vasculature. Any one of these alone is a major clinical challenge. In advanced cervical cancer, you are often managing all four simultaneously in a woman who is younger than your typical hospice patient and may have school-age children at home. Every clinical decision must account for that reality.
"When you walk into the room of a woman dying of cervical cancer, you need to know two things before anything else. First: this disease does things to the body that test everything you thought you knew about dignity — fistulas that leak urine and stool through the vagina, pelvic pain that doesn't respond to morphine alone, and hemorrhage that can be catastrophic without warning. You need a plan for all of it before you walk in. Second: she is probably younger than most of your patients, she may have children who don't fully understand what is happening, and she almost certainly knows that a Pap smear could have caught this. That knowledge sits in the room whether anyone says it out loud or not. Your job is to be clinically excellent and humanly present at the same time. There is no version of this visit where you can do one without the other."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Diagnostic Workup
- Pelvic exam with colposcopy and cervical biopsy — gold standard for tissue diagnosis
- Pap smear and HPV co-testing — screening tools; most cervical cancers reaching hospice were not caught by screening[21]
- MRI pelvis — best for local staging; assesses parametrial involvement, bladder/rectum invasion, lymph node status
- CT chest-abdomen-pelvis — metastatic staging workup
- PET-CT — lymph node and distant metastasis detection; increasingly used for treatment planning
- Cystoscopy and proctoscopy — if bladder or rectal invasion suspected; changes staging from IIIB to IVA
- EUA (examination under anesthesia) — used for clinical staging in settings without MRI access[6]
What to Look for in Hospice Records
- Prior radiation fields and dose — pelvic radiation causes permanent tissue changes that affect fistula risk, wound healing, and bowel function; an irradiated pelvis behaves differently in every clinical scenario
- Ureteral stent status — bilateral ureteral obstruction with stents in place requires stent management planning (exchange intervals, urosepsis risk, who manages them in hospice)
- Fistula history and type — vesicovaginal (VVF) and rectovaginal (RVF) fistulas require specific management strategies and family preparation
- Prior radical hysterectomy — altered pelvic anatomy affects pain patterns, bladder function, and obstruction presentation
- Prior chemotherapy agents — cisplatin neuropathy is cumulative; patients often arrive with significant peripheral neuropathy from prior chemoradiation[8]
- Molecular status — PD-L1 CPS score (pembrolizumab eligibility), HER2 status in adenocarcinoma
💡 FIGO 2018 Staging & Histology
- Stage I: Confined to cervix (IA1, IA2, IB1, IB2, IB3)
- Stage II: Beyond cervix but not to pelvic wall or lower vagina — IIB = parametrial invasion (critical prognostic distinction)
- Stage III: Pelvic wall, lower vagina, or hydronephrosis (IIIA, IIIB, IIIC1/C2 = lymph node involvement)
- Stage IVA: Invasion of bladder or rectum mucosa
- Stage IVB: Distant metastasis — lungs, liver, bone, supraclavicular nodes
- Histology: Squamous cell carcinoma (70%), adenocarcinoma (25%, slightly worse prognosis), adenosquamous (5%)[6]
Causes & Risk Factors
Modifiable and systemic risk factors. Relevant for family conversations and answering "why did this happen?"
HPV & Modifiable Risk Factors
- HPV infection: >99% of cervical cancers caused by high-risk HPV; HPV 16 (~60%) and HPV 18 (~15%) predominate; HPV vaccination prevents >90% of cervical cancers[3][4]
- Lack of cervical cancer screening: Pap smear and HPV co-testing detect precancerous lesions years before invasion; most fatal cases were never screened[21]
- HIV and immunosuppression: HIV-positive women have 6x higher cervical cancer risk and present at more advanced stages
- Tobacco smoking: Doubles risk of squamous cell carcinoma — direct carcinogenic effect on cervical epithelium plus immune suppression
- High parity: 3 or more full-term pregnancies associated with increased risk
- Long-term oral contraceptive use: >5 years modestly increases risk
Non-Modifiable & Systemic Factors
- Low socioeconomic status: The most powerful predictor of late-stage diagnosis — reflects screening access, not behavior[18]
- Race and ethnicity: Black American women have cervical cancer mortality rates 40% higher than white American women; Hispanic women have the highest incidence in the US; Indigenous and rural women have dramatically lower screening rates[19][20]
- Early age at first intercourse and multiple sexual partners: Increases cumulative HPV exposure
- These disparities are entirely driven by differential access to HPV vaccination, Pap screening, colposcopy, and specialty gynecologic oncology care — not by biology
❤️ For families: "Why did this happen?"
Cervical cancer is caused by a very common virus called HPV — most adults are exposed to it at some point in their lives. The cancer develops when the virus is not cleared by the immune system and is not detected by routine screening over many years. This was not caused by anything your loved one did wrong. In many cases, the healthcare system simply did not provide the screening that would have caught this early. That is a failure of the system — not of your family member.
⚕ Clinician note: The equity dimension
These disparities are entirely driven by differential access to HPV vaccination, Pap screening, colposcopy, and specialty gynecologic oncology care — not by biology. The woman dying of cervical cancer in your care is the face of what happens when a healthcare system fails to reach the most vulnerable. The hospice clinician does not correct that failure — but they must name it, and they must provide care that is unconditionally excellent regardless of where the patient falls in the system.[18][19]
Treatments & Procedures
What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.
Understanding the treatment history of a cervical cancer patient is essential because prior therapy — particularly pelvic radiation — permanently alters the clinical landscape. An irradiated pelvis has compromised tissue vascularity, impaired wound healing, fibrotic lymphatics, and radiation-damaged bladder and rectal mucosa. Every symptom you manage in hospice is filtered through this prior treatment reality.[7]
Early Stage (IA–IB1)
- Radical hysterectomy with pelvic lymph node dissection (Wertheim hysterectomy)
- Trachelectomy — fertility-sparing in selected Stage IA–IB1; know if performed as pelvic anatomy is significantly altered
- Cone biopsy — Stage IA1 only
- Key hospice implication: altered pelvic anatomy, possible lymphedema, nerve injury from surgery
Locally Advanced (IB2–IVA)
- Concurrent cisplatin-based chemoradiation — weekly cisplatin + external beam radiation + brachytherapy (standard of care)[7]
- Brachytherapy is the critical component — incomplete brachytherapy significantly worsens outcomes
- Pembrolizumab added to chemoradiation in high-risk locally advanced disease (KEYNOTE-A18)[12]
- Key hospice implication: prior radiation defines all subsequent pelvic complications — fistula risk, proctitis, cystitis, fibrosis
Recurrent/Metastatic (IVB)
- Pembrolizumab + chemotherapy ± bevacizumab — KEYNOTE-826 first-line; PD-L1 CPS ≥1 covers most patients[8]
- Cisplatin + paclitaxel ± bevacizumab — GOG 240; bevacizumab adds 3.7 months median OS but increases fistula risk from 1% to 8–15% in irradiated patients[9][30]
- Tisotumab vedotin — antibody-drug conjugate, second-line post-platinum (innovaTV 301)[11]
- Second-line: topotecan, irinotecan, docetaxel — limited activity[15]
Palliative Procedures
- Ureteral stenting — bilateral obstruction; percutaneous nephrostomy or retrograde stents; whether to stent is a goals-of-care conversation
- Palliative radiation for hemorrhage — hemostatic radiation highly effective even in previously irradiated patients using reirradiation protocols[37]
- Vaginal packing for hemorrhage — silver nitrate, Monsel's solution, gauze packing for active hemorrhage management
- Fistula management — surgical repair rarely feasible in irradiated tissue; urinary diversion or colostomy in selected patients
- Nephrostomy tube placement for bilateral obstruction when stenting fails
When Therapy Makes Sense
Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.
The therapeutic landscape for recurrent/metastatic cervical cancer has changed significantly with the addition of immune checkpoint inhibitors. Pembrolizumab combined with chemotherapy has become the first-line standard, and durable responses are possible in a meaningful subset of patients. Understanding when continued therapy genuinely benefits the patient — and when it does not — requires careful assessment of performance status, biomarker status, organ function, and patient goals.[8][10]
- 01First recurrence with PD-L1 CPS ≥1 and ECOG 0–1 — pembrolizumab + chemotherapy ± bevacizumab (KEYNOTE-826). The 24-month OS rate was 53% with pembrolizumab vs 42% with placebo. PD-L1 CPS ≥1 covers over 80% of cervical cancer patients. Meaningful survival benefit and durable responses are possible.[8][10]
- 02Bevacizumab addition in recurrent cervical cancer — improves OS by 3.7 months (GOG 240). However, in previously irradiated patients, the fistula risk increases to 8–15%. This risk-benefit discussion must happen explicitly and be documented before initiation. The patient must understand that the drug that extends her life may also create a fistula that profoundly alters its quality.[9][30]
- 03Tisotumab vedotin second-line in ECOG 0–1 post-platinum — innovaTV 301 demonstrated improved OS vs investigator-choice chemotherapy. Manageable toxicity profile including ocular toxicity requiring monitoring. A meaningful second-line option.[11]
- 04Palliative radiation for hemorrhage — even in hospice-eligible patients, a short hemostatic radiation course (1–5 fractions) that stops life-threatening vaginal hemorrhage is a comfort intervention. Response rates 70–90%. This conversation belongs at hospice enrollment, not during the hemorrhage crisis. Establish the radiation oncology relationship early.[37]
- 05Ureteral stenting in bilateral obstruction — when restoring renal function would meaningfully improve quality of life, stenting is an individualized comfort decision, not a disease-directed intervention. The conversation must include: stenting prolongs life but may prolong dying; the decision must be consistent with the patient's stated goals.
- 06Patient goals explicitly include life-prolongation with full prognosis understanding and ECOG 0–1 with adequate renal function (GFR >50 if cisplatin-based). A well-informed patient who chooses active treatment should receive it without judgment.[46]
When It Doesn't
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
Cervical cancer has one of the lowest rates of timely hospice referral among gynecologic malignancies. Many patients receive chemotherapy within 14 days of death. The reasons are complex — younger patient age, physician reluctance to discuss prognosis in younger women, the emotional weight of a preventable disease, and the false hope generated by each new line of therapy. Recognizing when treatment has crossed from benefit to burden is the most important clinical skill in this disease.[31]
- 01ECOG ≥3 — no evidence of survival benefit from systemic chemotherapy at this performance status. Toxicity without benefit. Hospice enrollment is appropriate.[15]
- 02Platinum-resistant recurrence — recurrence less than 6 months from platinum completion. Response rates to any subsequent therapy are below 15%. The data does not support continued cytotoxic chemotherapy outside of a clinical trial.
- 03Bilateral ureteral obstruction with declining renal function not amenable to stenting, or where stenting is inconsistent with patient goals — this represents a uremic trajectory. The kidneys are failing because the tumor has encased both ureters. Without intervention, this is a natural and typically comfortable dying process (uremic somnolence). Stenting must be an active choice, not a default.
- 04Fistula with sepsis or unmanageable hygiene burden — when quality of life has crossed the threshold where systemic therapy adds toxicity without meaningful benefit. A woman managing continuous urinary or fecal drainage through the vagina while receiving IV chemotherapy is experiencing compounded suffering.[30]
- 05Progression through pembrolizumab-based therapy and tisotumab vedotin — no established fourth-line standard with meaningful activity. Continued therapy at this point reflects hope, not evidence. Hospice enrollment is the evidence-based recommendation.
- 06Patient goals shift to comfort, presence, and time with children — when a fully informed patient says "I want to be home with my kids," that is not giving up. That is the clearest clinical decision in this entire disease trajectory. Honor it immediately.[41]
📋 Bevacizumab-fistula watershed
If a patient develops a vesicovaginal or rectovaginal fistula while on bevacizumab — which occurs in 8–15% of previously irradiated patients — this represents a quality-of-life watershed that often triggers the hospice transition. The fistula itself is rarely surgically correctable in irradiated tissue. Comfort management becomes the framework. This clinical reality must be discussed before bevacizumab is initiated — not after the fistula develops.[30]
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Hemostatic Radiation for Vaginal Hemorrhage
Grade APalliative RT: 1–5 fractions (various protocols: 10 Gy × 1, 4 Gy × 5, or 3 Gy × 10)
Palliative radiation is the most effective hemostatic intervention for cervical cancer hemorrhage. Response rates 70–90% with rapid onset. Reirradiation protocols exist for previously irradiated patients. Even in hospice-eligible patients, this conversation belongs at enrollment — establish radiation oncology contact before the hemorrhage crisis, not during it.[37]
Acupuncture for Pelvic Pain & Cisplatin Neuropathy
Grade B2–3 sessions/week for 4–8 weeks; maintenance 1×/week
Multiple RCTs demonstrate benefit for gynecologic cancer pelvic pain and cisplatin-induced peripheral neuropathy. Safe in this population. Pelvic cancer pain has a significant neuropathic component that responds to acupuncture in several controlled trials. Particularly valuable when opioid dose escalation alone is insufficient.[48]
Pelvic Floor Physical Therapy
Grade B1–2 sessions/week; home exercise program between sessions
Radiation-induced cystitis, proctitis, and pelvic floor dysfunction respond to targeted physical therapy. Even in advanced disease, reducing urinary urgency, rectal urgency, and pelvic floor spasm improves quality of life meaningfully. Assess feasibility based on performance status.[26]
Mind-Body / MBSR for Pelvic Pain & Anxiety
Grade BStructured 8-week MBSR program or adapted shorter protocol
Pelvic cancer pain has a significant psychological amplification component. Mindfulness reduces pain catastrophizing and urgency that worsens pelvic floor dysfunction. Particularly important in younger patients facing existential distress alongside physical symptoms.[39]
Topical Metronidazole for Fistula Odor
Grade BMetronidazole 0.75% gel applied to fistula area BID; activated charcoal dressings as adjunct
Topical metronidazole gel significantly reduces anaerobic bacterial odor from VVF and RVF fistulas. Activated charcoal dressings and bismuth-impregnated gauze also effective. This is one of the most dignity-restoring interventions in end-stage cervical cancer — inexpensive, effective within days, and transforms the patient's willingness to have family near her.[31]
Percutaneous Nephrostomy as Comfort Decision
Grade BInterventional radiology placement; tube exchange every 8–12 weeks
If ureteral stenting fails or is not anatomically possible, percutaneous nephrostomy restores renal function and reduces uremic symptoms. Hospice-compatible if consistent with patient goals and manageable at home. The decision framework is identical to stenting — it prolongs life and may prolong dying; the patient must understand both dimensions.[38]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to this diagnosis. Patients will use supplements — this section helps you have the right conversation.
"Every cervical cancer patient I've ever had was taking something — turmeric, green tea capsules, something from a health food store. The conversation isn't 'stop everything.' The conversation is: 'Show me what you're taking so I can make sure it's safe with your pain medications and doesn't make the bleeding worse.' That's it. Most of the time they're relieved someone asked without judging them."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Ginger | Grade B | 1 g/day capsule form; ginger tea 2–3 cups/day | Nausea from chemotherapy and systemic disease; particularly important given significant GI symptom burden from pelvic radiation sequelae | Safe; minimal interactions; may have mild antiplatelet effect at very high doses — clinically insignificant at recommended doses |
| Marshmallow Root | Grade C | 1–2 g dried root as tea TID; capsule 500 mg TID | Demulcent — soothes bladder and urethral mucosal irritation from radiation cystitis and fistula | Safe at food-source doses; no significant drug interactions |
| Slippery Elm | Grade C | 400–500 mg capsule TID; or bark tea | Mucilaginous coating for bowel mucosal irritation from radiation proctitis | Safe; no significant interactions; may slow absorption of oral medications — separate by 2 hours |
| Melatonin | Grade C | 1–5 mg PO QHS | Sleep and quality of life benefit; some radiosensitization signal in HPV-associated cancer preclinically | Safe at standard doses; minimal interactions; may enhance sedation with benzodiazepines |
| Aloe Vera Internal Gel | Grade C | 50–100 mL juice daily | Radiation-induced bowel and bladder mucosal soothing; some clinical data for radiation proctitis | Safe at food quantities; caution with electrolyte imbalance in cachectic patients; diarrhea at higher doses |
🚫 Avoid in This Diagnosis
- High-dose Fish Oil, Ginkgo, Vitamin E at high doses (>400 IU): Antiplatelet effect — compounded hemorrhage risk. Cervical cancer hemorrhage is one of the most feared clinical events in this diagnosis. Anything that impairs hemostasis is absolutely contraindicated in patients with known vascular tumor involvement.
- St. John's Wort: CYP3A4 inducer — drastically reduces blood levels of pembrolizumab and paclitaxel. Serious and poorly recognized interaction. Absolutely contraindicated if on or recently discontinued from systemic therapy.
- Echinacea and immunostimulant herbs: Theoretical immune activation may worsen pembrolizumab-related immune toxicities — colitis, pneumonitis, thyroiditis. Avoid in patients who have received immunotherapy.
- High-dose Vitamins C and E (supplemental doses): Theoretical interference with radiation mechanism if receiving palliative hemostatic radiation. Avoid during active radiation course.
- Cascara, Senna, and stimulant laxatives in fistula patients: Increased bowel motility worsens rectovaginal fistula symptoms and odor. Use osmotic laxatives instead — polyethylene glycol (MiraLax), lactulose.
Timeline Guide
A guide, not a prediction. Every patient's trajectory is shaped by histology, molecular profile, treatment response, and comorbidities.
This timeline reflects the typical trajectory of cervical cancer from curative-intent treatment through end of life. Individual trajectories vary based on stage at diagnosis, histology, molecular profile, treatment response, fistula development, and renal function. Squamous cell carcinoma and adenocarcinoma may follow somewhat different trajectories — adenocarcinoma tends to recur at distant sites more frequently. The presence of bilateral ureteral obstruction, established fistula, or hemorrhagic episodes significantly compresses the remaining timeline.[7][13]
YRS–
MOS
MOS
Early / Stable — Post-Curative Treatment
- Radical hysterectomy recovery or completion of chemoradiation and brachytherapy; surveillance pelvic exams every 3 months[22]
- Radiation sequelae developing: bladder frequency and urgency, bowel urgency and diarrhea, vaginal stenosis, peripheral neuropathy from cisplatin
- Functionally recovering but permanently altered by treatment; sexual dysfunction from radiation and surgery[26]
- Palliative care integration is almost never offered at this stage despite significant chronic symptom burden from treatment
MOS–
1 YR
1 YR
First Recurrence — Palliative Care Window
- First recurrence — usually within 2 years of primary treatment; pelvic recurrence most common (70%)
- Systemic therapy initiated: pembrolizumab + chemotherapy ± bevacizumab[8]
- Pelvic pain beginning or worsening; ureteral stent possibly placed
- Bevacizumab fistula risk discussion mandatory if irradiated pelvis[30]
- ECOG still adequate (0–2) but declining; this is the palliative care integration window and it is almost universally missed[46]
WKS–
MOS
MOS
Progression — Hospice Transition Window
- Progression through systemic therapy; pelvic pain requiring regular opioids[33]
- Fistula possibly established (especially if bevacizumab used in irradiated pelvis)
- Bilateral ureteral obstruction developing with rising creatinine — goals-of-care conversation about stenting
- ECOG declining to 2–3; hemorrhage risk increasing
- Hospice transition window — this is the correct enrollment point
- If children are at home, legacy work and family preparation must begin now[43]
DAYS–
WKS
WKS
Active Dying — Pre-Active Phase
- Pelvic hemorrhage risk highest — prepare family urgently with hemorrhage protocol[36]
- Fistula drainage ongoing — comfort management protocol must be in place
- Bilateral ureteral obstruction may cause uremic somnolence (if not stented — this is actually a comfortable dying process)
- Convert all medications to SQ route; profound fatigue; minimal oral intake
- Children may need specific preparation and support for what they will witness[43]
HRS–
DAYS
DAYS
Final Hours
- Possible vaginal hemorrhage if pelvic tumor is present — have midazolam drawn and hemorrhage protocol reviewed
- Cheyne-Stokes breathing; mottling of extremities; mandibular breathing
- Unresponsive or minimally responsive; auditory awareness may persist
- Children may be present — prepare them for what they will see and hear; age-appropriate language[43]
- Family presence is the clinical priority; everything else is secondary[41]
Medications to Anticipate
Symptom-targeted pharmacology for cervical cancer. What to have in the comfort kit, what to titrate first, and what the evidence supports.
Pelvic pain in cervical cancer is the dominant symptom driver and it is neuropathic in character. Lumbosacral plexopathy from tumor invasion of the sacral nerve roots produces sciatic-distribution pain that responds poorly to opioids alone. The medication strategy must address neuropathic pain (gabapentin/pregabalin), somatic/visceral pain (opioids), pelvic edema (dexamethasone), stent-related spasm (alpha-blockers), fistula odor (metronidazole), hemorrhage (tranexamic acid and emergency midazolam), and the full spectrum of end-of-life symptoms.[33][35]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Morphine / Hydromorphone | Opioid / Pelvic Pain + Dyspnea | Morphine 5–10 mg PO q4h; SQ 2–5 mg q4h; Hydromorphone 1–2 mg PO q4h | First-line. Pelvic cancer pain is often severe and requires high doses due to nerve plexus invasion. SQ preferred as oral route fails. Do not undertreat — pelvic cancer pain is among the most severe pain syndromes in hospice oncology.[48] |
| Gabapentin | Anticonvulsant / Neuropathic Pelvic Pain | 300 mg TID, titrate to 900 mg TID | Essential in this diagnosis. Lumbosacral plexopathy and cisplatin peripheral neuropathy are neuropathic and do not respond adequately to opioids alone. Start at enrollment — do not wait for opioid failure.[35] |
| Dexamethasone | Corticosteroid / Pelvic Edema, Appetite, Pain Adjunct | 4–8 mg PO/SQ daily | Reduces periureteral inflammation — may temporarily relieve partial ureteral obstruction. Bone and brain metastasis pain adjunct. Appetite stimulation. Taper if >2 weeks. |
| Tamsulosin | Alpha-blocker / Ureteral Stent Pain | 0.4 mg PO daily | Reduces ureteral stent-related pain and spasm. Underused in cervical cancer patients with ureteral stents. Monitor for orthostatic hypotension. |
| Metronidazole Gel 0.75% | Topical / Fistula Odor Management | Apply to fistula area BID | Among the most dignity-restoring comfort interventions available. Reduces anaerobic bacterial colonization causing characteristic foul odor. Combine with activated charcoal dressings. Order it every time you identify a fistula.[31] |
| Midazolam | Benzodiazepine / Hemorrhage Emergency + Terminal Agitation | 5–10 mg SQ immediately for catastrophic hemorrhage; 2.5–5 mg SQ PRN agitation | MUST be drawn, labeled, and at the bedside from day one of hospice enrollment for any patient with pelvic tumor burden. Non-negotiable. ⚠ Caution: Prepare family explicitly for hemorrhage protocol.[36] |
| Haloperidol | Antipsychotic / Nausea | 0.5–1 mg PO/SQ q8h | Opioid-induced and uremia-related nausea. Preferred first-line antiemetic in hospice for its dual anti-nausea and mild anxiolytic properties. |
| Ondansetron | 5-HT3 Antagonist / Nausea Adjunct | 4–8 mg PO/ODT q8h PRN | Second-line nausea adjunct. Useful when haloperidol alone insufficient. ⚠ Caution: constipating — add bowel regimen. |
| Lorazepam | Benzodiazepine / Anxiety | 0.5–1 mg PO/SQ PRN q4–6h | Pelvic symptoms and hemorrhage fear generate profound anxiety in younger patients. Low threshold for PRN use. Consider scheduled if anxiety is persistent. |
| Tranexamic Acid | Antifibrinolytic / Vaginal Bleeding | 1–1.3 g PO TID | Reduces hemorrhage volume in ongoing vaginal bleeding. ⚠ Caution: Stop if clot retention occurs in bladder. Contraindicated in active thromboembolic disease. |
| Glycopyrrolate | Anticholinergic / Terminal Secretions | 0.2 mg SQ q4h PRN | Reduces terminal secretions without CNS effects. Preferred over hyoscine in conscious patients. |
🌿 Symptom Management Decision Tree
Evidence-based · Hospice-adaptedSelect a symptom below to begin
What is the primary symptom to address?
🚨 Hemorrhage Emergency Protocol — Day One Obligation
Cervical cancer vaginal hemorrhage is one of the most feared and most preventable family trauma events in hospice. For any patient with pelvic tumor burden, prior hemorrhagic episodes, or large tumor mass: Midazolam 5–10 mg SQ must be drawn, labeled, and visibly accessible at the bedside from day one. Dark red or brown towels at bedside. The family MUST be briefed explicitly: what hemorrhage looks like, exactly what to do (stay present, administer midazolam if instructed, call the nurse, do not call 911, do not leave the patient alone). This conversation must happen at a good visit — not during the crisis. Write the protocol in the care plan. Review it at every visit. A family who is prepared for a hemorrhage event is not destroyed by it. A family who is not is.[36]
Clinician Pointers
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.
1
Fistula formation changes everything — manage it as a dignity crisis
A vesicovaginal fistula (urine draining continuously through the vagina) or rectovaginal fistula (stool and gas passing through the vagina) is not just a medical complication — it is a total dismantling of dignity. Manage it as both a clinical problem and a dignity crisis. Topical metronidazole for odor, containment products, skin barrier creams to prevent maceration, frequent linen changes, and explicit acknowledgment of what the patient is experiencing are all clinical interventions. Surgical correction is rarely feasible in irradiated tissue — do not offer false hope of repair unless gynecologic oncology has specifically confirmed it is possible.[28][30]
2
Bevacizumab in an irradiated pelvis is a fistula accelerant
If a patient on your caseload received bevacizumab as part of first-line recurrent therapy, know the fistula risk was 8–15%. Examine for fistula at every visit by asking directly about urinary or fecal drainage from the vagina. Do not wait for the patient to volunteer this information — shame prevents disclosure. Ask: "Have you noticed any leakage of urine or stool from your vagina that seems new or different?" Every visit.[30]
3
Pelvic pain is neuropathic — gabapentin is not optional
Lumbosacral plexopathy from tumor invasion causes sciatic-distribution pain that does not respond adequately to opioids alone. Add gabapentin early — at enrollment, not after opioid escalation fails. Consider dexamethasone for periureteral edema. Use alpha-blockers for stent pain. Escalating opioids in isolation when the pain is neuropathic is clinical frustration for both patient and clinician.[33][35]
4
Bilateral ureteral obstruction is a prognostic milestone and a goals-of-care conversation
When both ureters are obstructed, the decision to stent or not to stent is one of the most important comfort decisions in cervical cancer hospice care. Stenting restores renal function and may allow more time — but it also prolongs dying. Without stenting, uremic somnolence is a typically comfortable dying process. Have the conversation explicitly: "The disease is now affecting the kidneys. We need to decide together whether to place stents and what that means for the time ahead." Document the decision and honor it.
5
Ask about children at every intake — this is a clinical question
Before you close the clinical section of your intake visit, ask: "Are there children in the home? How old are they? Do they know what is happening?" These are not social work questions. They are clinical questions. The answers change your visit priorities, your family education focus, and the timeline of your legacy work. A woman with a 6-year-old at home needs a different care plan than a woman whose children are grown. Do not leave without asking.[43]
"The first time I walked into the room of a 38-year-old woman with a vesicovaginal fistula and two kids under 10, I realized that everything I thought I knew about end-of-life care was organized around the wrong patient. She didn't need me to manage her symptoms and leave. She needed me to sit down, look at her, and say: 'I know what's happening with the leaking. I know how hard that is. I have a plan for it, and I need you to let me help you.' She cried for ten minutes. Then we got to work."
— Waldo, NP
Psychosocial & Spiritual Care
Existential distress, depression screening, spiritual assessment, and goals-of-care communication. The symptom burden you can't see on a vitals sheet.
Psychosocial and spiritual distress in cervical cancer carries dimensions that are unique among hospice diagnoses. This is a disease that kills younger women — women with dependent children, active careers, and decades of unlived life. It is caused by a sexually transmitted virus, which generates shame that is pervasive and usually unspoken. It is almost entirely preventable, which generates a specific grief and anger in patients who know they were failed by the healthcare system. And it produces symptoms — fistula, hemorrhage, pelvic disfigurement — that attack dignity with particular cruelty. The psychosocial framework for cervical cancer must address all of these dimensions simultaneously.[27][42]
Disease-Specific Psychological Dimensions
Younger Patients with Dependent Children
Grade B- Cervical cancer kills women in their 30s and 40s; many have children under 18 at home
- The psychosocial framework for a dying mother is categorically different from the framework for an elderly patient[43]
- Legacy work must begin at enrollment: letters to children for future milestones (graduations, weddings, birthdays), video recordings, photo projects, memory books
- Do not wait until the patient is too weak to participate — legacy work requires energy, emotional capacity, and time
- Children grieve better when included in age-appropriate truth-telling than when shielded from reality[43]
- Mirtazapine 7.5 mg QHS — first-line for depression in this population; addresses depression, insomnia, and anorexia simultaneously
HPV Shame, Health Equity Grief & Fistula Dignity
Grade B- HPV shame: Ask directly — "Some women feel embarrassed about how cervical cancer starts — have you ever felt that way?" Address it clinically: HPV is nearly universal (80% of sexually active people will have it); this is not a moral failure, it is a failure of the system that did not vaccinate or screen[3]
- Health equity anger: Many patients know they were failed by the system; they know a Pap smear would have caught this; that anger is legitimate and it is not the hospice clinician's job to defend the system — witness the injustice and provide extraordinary care[18]
- Fistula shame: Continuous leakage of urine or feces through the vagina is profoundly dehumanizing; patients hide this symptom because of shame; address it explicitly, normalize it clinically, provide management before shame prevents disclosure
- Sexual identity loss: Radical hysterectomy, radiation fibrosis, fistula, and pelvic pain collectively dismantle sexual function and identity; for younger women this loss is profound — do not skip it[26][27]
Spiritual Assessment
A woman in her 30s or 40s dying of a preventable disease while her children are young does not fit any theology of fairness or meaning easily. The spiritual question is not "why did God allow this" but something more raw and specific: "who will take care of my children?" Chaplain involvement from enrollment is essential and should be framed around legacy and children, not only around dying. Use the FICA framework. Ask: "What gives you strength during this time?" and "What are you most worried about for your children?" These open spiritual conversation without assuming any tradition.[40]
Goals-of-Care Communication
Opening the Conversation
- "What is your understanding of where things stand with your illness?" — assesses illness understanding before prognostic disclosure
- "What are you hoping for?" — in younger patients this often reveals children-centered goals that change the care plan
- "What are you most afraid of?" — in cervical cancer this is often specific: hemorrhage, fistula worsening, children seeing her suffer, children forgetting her
- "If things got worse, what would matter most to you?" — elicits priorities without triggering defensiveness
Communication Pitfalls
- Don't use language of surrender: "Stopping treatment" vs "shifting the focus of care"
- Don't say "there's nothing more we can do" — there is always more to do
- Don't conflate hospice with giving up — frame around what hospice adds
- Don't assume the family knows about the fistula or hemorrhage risk — ask what they've been told
- For younger patients: avoid comparing their situation to elderly patients; their grief is specific and deserves specific acknowledgment
Suicidal Ideation & Hastened Death Requests
Passive wish for death is common in younger cervical cancer patients and is often existentially appropriate — "I'm ready to go" in a 40-year-old with dependent children carries a different weight than in an 85-year-old. Assessment requires careful distinction between passive wish for death, active suicidal ideation with plan, and medical aid in dying requests. The intersection of young motherhood, physical disfigurement from fistula, and terminal prognosis creates a specific risk profile for severe psychological distress. Screen actively. Engage psychiatry and chaplaincy early.[40]
Clinical Pearl
"Ask every cervical cancer patient directly: 'Do you have children at home? How old are they? What do they know about what is happening?' Then stop talking and listen. The answer to those three questions tells you everything about what this woman needs from hospice that is different from every other patient on your caseload."
"I've cared for a lot of dying patients. But the ones that changed me — the ones I carry — are the young mothers with cervical cancer. A 36-year-old woman writing birthday letters to a daughter who won't read them for twenty years. A 42-year-old trying to explain to a 7-year-old why mommy can't pick him up anymore. You sit with that. You don't rush it. You don't redirect it to clinical tasks. You sit with it, and you let it change how you do every single visit after that."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
You are caring for someone you love through one of the most difficult medical situations any family can face. Cervical cancer at end of life can involve symptoms that are frightening and hard to understand. This guide will help you know what to expect, what you can do, and when to call for help. You are not alone — the hospice team is here with you every step.
What You May See
- Severe pelvic pain — this is manageable with medication; do not wait to report pain that is not controlled. If she is grimacing, restless, or saying the pain is worse, call the nurse. There is always more we can do for pain.
- Leakage of urine or bowel contents in ways that seem wrong or unexpected — this is a known complication of the disease called a fistula. Your nurse needs to know about it. It is not her fault and it is treatable for comfort. Do not let embarrassment prevent you from reporting it.
- Vaginal bleeding — ranges from spotting to heavy. Tell the nurse the amount and color. Do not panic, but do call. There is a medication at the bedside for heavy bleeding.
- Swelling of the legs — lymphedema from pelvic lymph node involvement is common. Elevation and compression help. Ask the nurse about positioning.
- Profound fatigue — sleeping most of the day is expected and normal at this stage. It is not laziness or depression. Her body is using all its energy.
- Nausea and loss of appetite — small offerings of favorite foods; do not push eating. Appetite loss is the disease, not a choice.
How You Can Help
- Change linens and pads regularly if drainage is occurring — your nurse will provide containment products and teach you skin care to prevent irritation. Protect her dignity in all hygiene care — ask permission, provide privacy, let her guide what she is comfortable with.
- Keep the pelvic area clean and dry — your nurse will advise on products. Barrier creams prevent skin breakdown. This is important clinical care, not just comfort.
- Report any change in bleeding immediately — especially if it becomes heavier or continuous. The nurse has an emergency medication ready at the bedside for this.
- If children are in the home — ask the nurse and social worker for help explaining what is happening in age-appropriate language. Children grieve better when they are told the truth gently than when they are kept in the dark.[43]
- Be present without needing to fix things — she knows you are there. Your presence is the most powerful medicine in this room. Touch her hand. Sit quietly. That is enough.[41]
📞 Call the nurse immediately if you see:
Heavy vaginal bleeding that does not slow down — call the nurse immediately. The emergency medication (midazolam) is at the bedside. Stay present, administer if the nurse instructs you by phone, do not leave her alone, do not call 911 unless the nurse directs you to. Inability to urinate despite feeling the urge, especially if a catheter or stent is in place — call the nurse. Fever above 101°F with shaking chills — possible infection requiring assessment. Unable to be woken or significant change in responsiveness.
🙏 You are caregiving for someone who is younger than this disease should ever reach. That is a specific injustice and a specific grief. What you are doing — staying present through symptoms that are frightening and hard to manage, protecting her dignity when the disease makes that difficult, being her advocate when shame might keep her silent — is not ordinary caregiving. It is extraordinary love. If there are children in the home: they are watching how you love her. That will matter to them for the rest of their lives. You are not alone in this. We are here with you.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01Fistula is a dignity crisis before it is a clinical problem. When you find out your patient has a vesicovaginal or rectovaginal fistula, your first clinical move is to ask how she is managing it emotionally, not just physically. The shame of continuous urinary or fecal leakage through the vagina prevents most women from telling you how bad it really is. They will minimize it. They will say it's "not that bad." It is that bad. Ask directly: "How are you coping with the leaking? Is it affecting how you feel about yourself?" Then normalize it: "This is the disease. This is not your body failing you — this is what the tumor does. And we have ways to make it much better." Have your management plan ready before she answers — metronidazole gel for odor, containment products, skin barriers, scheduled linen changes. Lead with dignity. The clinical management follows.
- 02Ask about fistula at every visit in bevacizumab-treated patients. If your patient received bevacizumab in an irradiated pelvis, the fistula risk is 8–15%, and it may not have been present at enrollment. It can develop weeks to months after treatment. Ask every visit: "Have you noticed any new leaking — urine or stool — from your vagina?" She will not volunteer this information. Shame prevents disclosure and you must open the door every single time. If the answer changes, you need to be ready with a management plan that same visit.
- 03Hemorrhage protocol is a day-one obligation. Write it in the care plan. Review it with the family at intake. Have midazolam drawn in a syringe, labeled with the dose and instructions, and placed visibly at the bedside with dark-colored towels before you leave the first visit. Teach the family exactly what hemorrhage looks like, exactly what to do — stay with her, give the medication if you've been trained, call us, do not call 911 — and exactly what will happen when they call. Review this protocol at every visit. A family that has been prepared for a hemorrhage event is frightened but not destroyed. A family that has not been prepared is traumatized for life. This is entirely in your hands.
- 04Pelvic pain is neuropathic. Lumbosacral plexopathy from tumor invasion of the sacral nerve roots produces a shooting, burning, electric pain that radiates down the leg in a sciatic distribution. Morphine takes the edge off but it does not resolve it. You will watch a patient on escalating doses of morphine still reporting 7/10 pain and wonder what you're doing wrong. What you're doing wrong is not adding gabapentin. Start gabapentin 300 mg TID at enrollment and titrate to 900 mg TID. Add dexamethasone 4 mg daily if periureteral edema is contributing. Use tamsulosin if ureteral stents are in place. Neuropathic pain requires a neuropathic strategy.
- 05Younger patients need legacy work started at enrollment, not at the end. If your patient has children, the memory-making work begins on visit one. Letters to children for future milestones — their first day of high school, graduation, wedding day, the birth of their first child. Voice recordings. Video messages. Photo albums. A recipe box. Whatever matters to her. Do not wait until she is too weak to hold a pen or too exhausted to speak clearly into a phone. Legacy work requires energy, cognitive clarity, and emotional presence — all of which diminish as the disease progresses. Start on day one. The social worker and chaplain should be involved from enrollment.
- 06The HPV shame conversation must happen. Most cervical cancer patients carry it silently — the sense that their cancer is somehow their fault because it was caused by a sexually transmitted virus. Some were told this explicitly by family members. Some absorbed it from the culture. Ask directly: "Some women feel embarrassed or ashamed about how cervical cancer starts. Have you ever felt that way?" Then address it with clinical directness: HPV is nearly universal. Eighty percent of sexually active people will be exposed to it in their lifetime. The difference between the women who get cervical cancer and the women who don't is not sexual behavior — it is screening and vaccination. This was a failure of the healthcare system, not a failure of character. Say it out loud. Mean it. She needs to hear it from a clinician.
- 07Bilateral ureteral obstruction is both a prognostic milestone and a goals-of-care decision. When you see bilateral hydronephrosis on imaging or rising creatinine without another explanation, sit down with the patient and family and say: "The disease is now pressing on the tubes that drain the kidneys. We have a decision to make together. We can place stents to keep the kidneys working, which may give more time — but it also means more procedures, possible infections, and it extends a process that is already difficult. Or we can focus entirely on comfort, knowing that the kidneys will gradually slow down in a way that is usually quite peaceful." Document the conversation. Document the decision. Honor it without second-guessing.
- 08Metronidazole topical gel for fistula odor is one of the most powerful dignity-restoring interventions in hospice medicine. It costs almost nothing. It works within 48–72 hours. It transforms the patient's willingness to have family near her. And it is almost never ordered because clinicians either don't think of it or don't recognize how devastating the odor is to the patient's sense of self. Order it every single time you identify a fistula — VVF or RVF. Apply 0.75% gel to the fistula area and surrounding tissue BID. Add activated charcoal dressings over containment pads. This one intervention can change the entire trajectory of a patient's relationship with her own body and her family.
- 09Children in the home require a clinical plan — not just a social work referral. At your intake visit, ask specifically: how many children, how old are they, what do they understand about what is happening, and what does the patient want them to know. Build the answers into your care plan as clinical priorities. A 4-year-old and a 14-year-old need completely different conversations. The 4-year-old needs concrete language: "Mommy's body is very sick and the doctors can't fix it." The 14-year-old may need to hear the word "dying" and be given permission to be angry about it. Neither of them should be finding out in a crisis. This is clinical work. Treat it that way.
- 10The equity dimension is the context for this entire visit. The woman dying of cervical cancer in front of you was almost certainly failed by a system that had the tools to save her life. The Pap smear existed. The HPV vaccine existed. The colposcopy referral pathway existed. These tools were available and they did not reach her — because of where she lived, what insurance she had, what language she spoke, or what color her skin was. Your job is not to fix that injustice. Your job is not to feel guilty about it. Your job is to provide unconditionally excellent care in its aftermath — to make her remaining time as comfortable, dignified, and present with the people she loves as possible. That is the only answer the bedside has for a system-level failure. Make it count.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide. CA Cancer J Clin. 2021;71(3):209-249.
2
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.
3
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
4
Lei J, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383(14):1340-1348.
5
Falcaro M, Castañon A, Ndez-Berman ND, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence. Lancet. 2021;398(10316):2084-2092.
6
Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2021 update (FIGO staging). Int J Gynaecol Obstet. 2021;155(Suppl 1):28-44.
7
Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169-182.
8
Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826). N Engl J Med. 2021;385(20):1856-1867.
9
Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer (GOG 240). N Engl J Med. 2014;370(8):734-743.
10
Monk BJ, Colombo N, Tewari KS, et al. First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826. J Clin Oncol. 2023;41(36):5505-5511.
11
Coleman RL, Lorusso D, Gennigens C, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 301). Lancet. 2023;401(10376):512-524.
12
Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer (KEYNOTE-A18). Lancet. 2024;403(10434):1341-1350.
13
Tewari KS, Sill MW, Monk BJ, et al. Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with/without bevacizumab (GOG 240). Gynecol Oncol. 2015;136(3):505-510.
14
Mayadev JS, Ke G, Oaknin A, et al. Global impact of adding concurrent pembrolizumab to chemoradiotherapy for locally advanced cervical cancer in KEYNOTE-A18. Int J Radiat Oncol Biol Phys. 2024;119(1):42-52.
15
Tewari KS, Monk BJ. Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005;7(6):419-434.
16
Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection. JAMA. 2007;298(7):743-753.
17
Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018. Lancet Glob Health. 2020;8(2):e191-e203.
18
Freeman HP, Wingrove BK. Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities. NIH Pub. No. 05-5282. 2005.
19
Buskwofie A, David-West G, Clare CA. A Review of Cervical Cancer: Incidence and Disparities. J Natl Med Assoc. 2020;112(2):229-232.
20
Rauh-Hain JA, Clemmer JT, Bradford LS, et al. Racial disparities in cervical cancer survival over time. Cancer. 2013;119(20):3644-3652.
21
Benard VB, Thomas CC, King J, et al. Vital Signs: Cervical Cancer Incidence, Mortality, and Screening — United States, 2007–2012. MMWR Morb Mortal Wkly Rep. 2014;63(44):1004-1009.
22
Elit L, Fyles AW, Devries MC, et al. Follow-up for women after treatment for cervical cancer. Curr Oncol. 2009;16(1):56-61.
23
Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(1):64-84.
24
Randall TC, Ghebre R. Challenges in Prevention and Care Delivery for Women with Cervical Cancer in Sub-Saharan Africa. Front Oncol. 2016;6:160.
25
Chuang LT, Temin S, Camacho R, et al. Management and Care of Women With Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline. J Glob Oncol. 2016;2(5):311-340.
26
Pfaendler KS, Wenzel L, Engeler V, et al. Cervical cancer survivorship: long-term quality of life and social support. Clin Ther. 2015;37(1):39-48.
27
Vistad I, Fosså SD, Dahl AA. A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol. 2006;102(3):563-572.
28
Hilton P, Cromwell DA. The risk of vesicovaginal and urethrovaginal fistula after hysterectomy performed in the English National Health Service. BJOG. 2012;119(12):1447-1454.
29
Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734-743.
30
Bizzarri N, Monk BJ, Tewari KS. Fistula risk with bevacizumab in advanced cervical cancer: a systematic review and pooled analysis. Gynecol Oncol. 2021;161(1):312-318.
31
Mishra K. Gynaecological malignancies from palliative care perspective. Indian J Palliat Care. 2011;17(Suppl):S45-S51.
32
Meraner V, Gamper EM, Grahmann A, et al. Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy. BMC Cancer. 2012;12:77.
33
Correa-Alfonso CM, Castro-Sandoval A. Pelvic pain in cervical cancer: pathophysiology and management. Curr Opin Support Palliat Care. 2020;14(3):180-186.
34
Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69(1-2):1-18.
35
Portenoy RK, Ahmed E. Cancer Pain Syndromes. Hematol Oncol Clin North Am. 2018;32(3):371-386.
36
Shinde S, Gordon P, Engstrom C, Berman M. Hemorrhagic complications of gynecologic cancer. Curr Oncol Rep. 2003;5(6):479-489.
37
Biswal BM. Hemostatic radiotherapy in cervical cancer. World J Clin Oncol. 2017;8(1):23-29.
38
Mishra SK, Singh P. Cervical cancer screening and management in palliative care setting. Indian J Palliat Care. 2018;24(Suppl 1):S45-S48.
39
Clark D. Total pain: the work of Cicely Saunders and the hospice movement. Am Pain Soc Bull. 2000;10(4):13-15.
40
Chochinov HM, Hack T, Hassard T, et al. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol. 2005;23(24):5520-5525.
41
Steinhauser KE, Christakis NA, Clipp EC, et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA. 2000;284(19):2476-2482.
42
Wenzel LB, Donnelly JP, Fowler JM, et al. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology. 2002;11(2):142-153.
43
Christ GH, Christ AE. Current approaches to helping children cope with a parent's terminal illness. CA Cancer J Clin. 2006;56(4):197-212.
44
Lee GL, Woo IM, Goh C. Understanding the concept of a "good death" among bereaved family caregivers of cancer patients in Singapore. Palliat Support Care. 2013;11(1):37-46.
45
Luckett T, Phillips J, Agar M, et al. Elements of effective palliative care models: a rapid review. BMC Health Serv Res. 2014;14:136.
46
Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742.
47
Kumar SP. Utilization of brief pain inventory as an assessment tool for pain in patients with cancer. Indian J Palliat Care. 2011;17(2):108-115.
48
Paice JA, Portenoy RK, Lacchetti C, et al. Management of Chronic Pain in Survivors of Adult Cancers: ASCO Clinical Practice Guideline. J Clin Oncol. 2016;34(27):3325-3345.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.